Ibex Expands U.S. Footprint with HNL Lab Medicine Partnership

Ibex Medical Analytics (Ibex) has formed a strategic collaboration with HNL Lab Medicine to deploy its advanced artificial intelligence (AI) solutions, Ibex Prostate for biopsies and transurethral resection of the prostate (TURP).

The deployment marks a significant milestone in HNL Lab Medicine’s digital transformation, according to the company. Since 2023, HNL Lab Medicine has operated a digital pathology practice combining Proscia’s Concentriq platform and Leica Biosystems’ high-throughput imaging hardware.

“HNL Lab Medicine is unique because we partner closely with health systems, embedding members of our team within their organizations while operating at the scale of a full-service clinical laboratory,” HNL Lab Medicine Chief Medical Officer Dr. Jordan Olson said. “That collaboration gives us insight into where innovation can make the biggest difference, which is why integrating Ibex’s AI is such a powerful step forward for our pathologists.”

Through this collaboration, HNL Lab Medicine is adding specialized AI capabilities to its diagnostic suite. Ibex Prostate helps pathologists detect and grade cancer and other clinically relevant findings in both core needle biopsies and TURPs, acting as a high-precision diagnostic aid and safety net to support the pathologist’s final review and ensure no suspicious lesion is overlooked. This initial validation and deployment, as part of the HNL Lab Medicine Lab Developed Test (LDT) workflow in prostate cancer, establishes a foundation for an evolving partnership aimed at advancing AI-powered diagnostics.

“We are thrilled to partner with HNL Lab Medicine, an organization that exemplifies the future of pathology,” Ibex Medical Analytics CEO Yair Heller said. ” HNL Lab Medicine’s ability to operate as a high-volume independent lab while maintaining the clinical rigor of a health system makes them an ideal partner for our technology. By integrating Ibex’s AI into their established digital workflow, HNL Lab Medicine is ensuring that their pathologists have advanced tools available to provide timely, high-confidence results for every patient.”

Ibex Medical Analytics aims to transform cancer diagnostics with clinical-grade, AI-powered pathology solutions. Ibex empowers clinicians to provide accurate, timely, and personalized diagnoses for every patient. Pathologists worldwide use Ibex to improve diagnostic accuracy, automate quality control, and streamline workflows, while the platform also supports advanced biomarker discovery. The Ibex platform includes solutions that are CE-IVD certified and registered with MHRA, TGA, ANVISA, AMAR, and Swissmedic. It includes a U.S. Food and Drug Administration (FDA)-cleared solution and others that are Research Use Only (RUO) in the United States. The Ibex suite includes solutions used by HNL Lab Medicine as part of a Laboratory Developed Test (LDT), which has not been cleared or approved by the FDA.

Operating for more than 25 years, HNL Lab Medicine is a multi‐regional, full‐service medical laboratory providing testing and related services to physician offices, hospitals, long‐term care facilities, employers, and industrial accounts. HNL Lab Medicine has more than 50 patient service centers in Pennsylvania and has 33 acute care laboratories within its partners’ hospital sites. More than 2,200 employees, including over 109 board-certified pathologists and scientific directors, help provide high-quality, advanced diagnostic testing.